Monoprost (Latanoprost)

Latanoprost is a prostaglandin F2α analogue that binds to FP receptors in the ciliary body. Activation of these receptors remodels the extracellular matrix, increasing uveoscleral outflow of aqueous humor. The resulting increase in fluid drainage lowers intra‑ocular pressure, which is the primary therapeutic goal in glaucoma management.

The dosing regimen for Monoprost is determined by the prescribing ophthalmologist. Typically, one drop is instilled into the affected eye(s) once daily in the evening, but the exact frequency and duration are individualized based on the patient’s intra‑ocular pressure response and clinical assessment. Patients should follow the prescriber’s instructions precisely.

Safety data for latanoprost in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Because systemic absorption is minimal but not negligible, the drug should only be used during pregnancy or while breastfeeding if the potential benefit justifies the potential risk, and after consultation with a healthcare professional.

To place an order, submit an enquiry on the Monoprost product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and assistance with import documentation.

Monoprost belongs to the prostaglandin analogue class, which generally offers once‑daily dosing and a strong IOP‑lowering effect compared with beta‑blocker or carbonic anhydrase inhibitor drops. Compared with other prostaglandin analogues such as travoprost or bimatoprost, latanoprost has a similar efficacy profile, but individual response and side‑effect tolerability may vary, so clinicians choose based on patient factors.

Monoprost eye drops should be stored at room temperature, below 25 °C, in the original container. Keep the bottle tightly closed, protect it from direct sunlight and moisture, and avoid freezing. Once opened, use within the period specified on the label, typically 4–6 weeks, and discard any solution that appears discolored or contains particles.

Monoprost is applied topically to the eye. The patient should wash hands, tilt the head back, gently pull down the lower eyelid to create a pocket, and instill one drop into the conjunctival sac of the prescribed eye(s). Close the eye gently for a few seconds without blinking, and avoid touching the tip of the bottle to the eye or any surface to maintain sterility.

While generally well tolerated, Monoprost can rarely cause serious ocular events such as uveitis, macular edema, or a pronounced deepening of the anterior chamber that may precipitate angle‑closure glaucoma. Patients should report sudden vision changes, eye pain, redness, or swelling promptly. Systemic adverse effects are uncommon but may include hypersensitivity reactions.

Monoprost is contraindicated in patients with known hypersensitivity to latanoprost or any component of the formulation. It should be used with caution, or avoided, in individuals with active intra‑ocular inflammation, a history of herpetic eye disease, or recent ocular surgery, as the drug may exacerbate inflammation or interfere with wound healing. A healthcare professional must evaluate suitability before prescribing.